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Electrocardiographic left ventricular hypertrophy is not 
associated with increased in-hospital adverse events in 
patients with first Non-ST segment elevation myocardial 
infarction: A single center study 
 
Abstract 
Background: There is conflicting data about prognostic implication of 
electrocardiographic (ECG) left ventricular hypertrophy (LVH) in patients with first non- 
ST-segment elevation myocardial infarction (NSTEMI). We aimed to examine the 
association of left ventricular hypertrophy (LVH) on admission electrocardiogram with 
adverse outcomes in patients with NSTEMI. 
Methods: In the present study, 460 patients (77.5% males with mean age of 65.44±13.15 
years) with first NSTEMI were evaluated. ECG left ventricular hypertrophy (LVH) was 
diagnosed based on Sokolow-Lyon voltage criteria. Baseline laboratory and clinical 
results, angiographic data, as well as in- hospital adverse events were compared between 
the patients with and without LVH. 
Results: Electrocardiographic LVH was observed in 74 (16.1%) patients. Patients with 
LVH had higher admission systolic blood pressure (132.91±21.08 vs 125.80±21.78; 
P=0.01) and higher peak troponin (6.42±1.03 vs 4.41±0.28; P=0.004), but less likely to 
undergo coronary angiography (54.1% vs 66.8%; P=0.03) .Patients with electrocardiographic 
LVH had similar in-hospital mortality (5.4% vs 3.6%, P=0.5) and heart failure/ pulmonary 
edema (2.7% vs 2.07%, P=0.6) compared to patients without LVH. 
Conclusion: The present study showed that among the patients with first NSTEMI, 
electrocardiographic LVH was not associated with increased in-hospital adverse events. 
Keywords: Non ST-segment elevation myocardial infarction (NSTEMI), Left ventricular 
hypertrophy (LVH), Electrocardiography (ECG), in-hospital mortality 
 
Citation: 
Bakhtiari F, Davarmoin G, Ghaffari S, Aslanabadi N. Electrocardiographic left ventricular 
hypertrophy is not associated with increased in-hospital adverse events in patients experiencing with 
first Non-ST segment elevation myocardial infarction: A single center study. Caspian J Intern Med 
2019; 10(3):289-294. 
 
 
Electrocardiographic evidence of left ventricular hypertrophy (LVH) is an 
independent and powerful determinant of cardiovascular death. This finding is often 
associated with a high probability of blood pressure-caused cardiovascular complications 
such as coronary artery disease, heart failure, stroke, and overall mortality (1-6). Left 
ventricular hypertrophy is caused by long-term and often untreated hypertension. By 
progressing LVH, the oxygen requirements of myocardium has increased, which can 
worsen supply-demand mismatch and potentially leads to acute coronary events (7). 
Therefore, diagnosis of patients with LVH is an important component of clinical risk 
reduction strategies in hypertensive patients. Numerous studies evaluated the relationship 
between electrocardiographic LVH and clinical outcomes in patients with ST-segment 
myocardial infarction (STEMI) or non-ST segment myocardial infarction. 
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Although many of these studies showed association 
between electrocardiographic LVH and cardiovascular 
outcomes like death and heart failure during hospital course 
and long-term follow-up (8-11), others showed that LVH in 
electrocardiogram had no prognostic implication (12-14). 
Given the contradiction in previous studies, we investigated 
the effect of electrocardiographic LVH on the in-hospital 
outcomes of patients with first NSTEMI. 
 
 
Methods 
In the present study, all patients admitted with a 
diagnosis of non-ST segment elevation myocardial infarction 
between January 2015 and March 2017 in our tertiary center 
in northwest of Iran were enrolled. The diagnosis of 
NSTEMI was made using the third universal definition of 
myocardial infarction (15): typical anginal chest pain, 
elevated cardiac enzymes and ST-segment depression or T 
wave inversion. We excluded patients with a non-
interpretable electrocardiogram, Left bundle branch block, 
acute ST-segment myocardial infarction, Paced rhythm, 
previous history of myocardial infarction, and previous 
history of any type of revascularization including coronary 
artery bypass grafting or percutaneous coronary intervention. 
 All demographic and clinical findings, including age, 
gender, coronary risk factors, history of angina, history of 
medications, and hemodynamic status during initial 
presentation, including systolic blood pressure (SBP) and 
heart rate were recorded. Moreover, laboratory data and 
coronary angiography results as well as revascularization 
procedures were recorded. Major adverse cardiovascular 
events (MACE) were defined as cardiovascular mortality, 
reinfarction and heart failure. LVH on ECG was defined 
based on Sokolow and Lyon voltage criteria: S amplitude in 
lead V1 plus R amplitude in lead V5 or V6 ≥35 mm and/or R 
amplitude in lead V5 or V6 >26 mm (16). The present study 
complied with the Declaration of Helsinki and was approved 
by the institutional review board of our center and all 
patients gave written informed consent. 
Statistical analysis: Categorical variables were described as 
frequency and percentage, and continuous variables, as 
mean± standard deviation. Chi-square test and Fisher's exact 
test were used to compare categorical variables between 
groups with and without electrocardiographic LVH, and 
independent t-test was used to compare the continuous 
variables. Furthermore, multivariate logistic tests were used 
to determine independent predictors of in-hospital 
complications as defined among the variables associated 
with p<0.05 in univariate analysis. In the present study, a p-
value less than 0.05 was considered significant. All data 
were analyzed using SPSS 17 software.  
 
 
Results 
In the present research, 460 patients consisting of 306 
(66.5%) males and 154 (33.5%) females with the mean age 
of 65.44±13.5 years were evaluated. Based on Sokolow and 
Lyon voltage criteria, LVH was observed in 74 (16.1%) 
patients. Basic and laboratory findings of patients with and 
without LVH are presented in table 1. 
 
Table 1. Baseline characteristics of the study population 
 
 LVH* 
N=74 
No LVH 
N=386 
p-
value 
Age (years) 67.52±14.87 65.08±12.82 0.1 
Female, n (%) 18(24.3%) 136(35.2%) 0.06 
Hypertension, n (%) 42(56.8%) 239(61.9%) 0.4 
Diabetes mellitus, n (%) 34(45.9%) 132(34.2%) 0.05 
Hyperlipidemia, n (%) 12(16.2%) 64(16.6%) 0.9 
Previous angina, n (%) 23(31.08%) 112(29.01%) 0.7 
Previous stroke, n (%) 2(2.7%) 14(3.6%) 0.6 
Heart rate (beats/min) 80.47±16.06 84.56±19.2 0.08 
Systolic blood pressure 
(mm Hg) 
132.91±21.08 125.80±21.78 0.01 
Killip class I, n (%) 61(82.4%) 305(79.01%) 0.6 
LV ejection fraction (%) 43.1±3.8 45.1±3.6 0.3 
More than Moderate 
Mitral regurgitation  
24(31.5%) 123(31.8%) 0.9 
Peak Creatine kinase-
MB (U/L) 
136.69±34.04 74.97±5.03 0.001 
Peak Troponin I  (ng/ml)  6.42±1.03 4.14±0.28 0.004 
Creatinine (mg/dl) 1.19±0.64 1.35±1.25 0.3 
Medication use before 
admission 
   
Aspirin, n (%) 26(35.1%) 131 (33.9%) 0.8 
Beta-blocker, n (%) 40(54.1%) 171(44.3%) 0.1 
Angiotensin-converting 
enzyme inhibitor, n (%) 
8(10.8%) 23(5.9%) 0.1 
Calcium antagonist, n (%) 8(10.8%) 24(6.2%) 0.2 
Nitrate, n (%) 14(18.9%) 50(12.9%) 0.1 
*LVH: Left ventricular hypertrophy 
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  Patients with LVH presented with higher SBP and had 
higher levels of peak Troponin and CK-MB. Other 
characteristics and risk profile and medication history were 
similar between groups. Also, patients with LVH underwent 
fewer catheterizations than those without LVH (54.1% vs 
66.8%; P=0.03). There was no difference regarding 
advanced coronary artery stenosis (LM/3VD) between 
patients with versus LVH (P0.26). (figure1) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure1: Coronary artery involvement in patients with 
and without LVH 
NLCAG: NL coronary angiography, 1VD: Monovessel disease, 2VD: two-
vessel disease, 3VD: three vessel disease, LM: left main coronary artery 
stenosis LVH: left ventricular Hypertrophy, CAD: coronary artery disease 
 
 
Most of patients underwent coronary  
 
 
 
63) (figure2). 
 
 
 
 
 
 
 
Figure 2: Revascularization procedure between patients 
with and without LVH 
LVH: left ventricular hypertrophy; CABG: coronary artery bypass graft 
surgery; PCI: percutaneous coronary intervention; MFU: medical follow-up 
Most of patients underwent coronary angioplasty as 
revascularization procedure. Percutaneous or surgical 
revascularization rate was not different between groups (p = 
0.63) (Figure2). Patients with electrocardiographic LVH had 
similar in-hospital mortality (5.4% vs 3.6%, P=0.4), heart 
failure/ pulmonary edema (2.7% vs 2.07%, P=0.6) and Re-
MI compared to patients without LVH (1.3% vs 0.25%, 
p=0.2) (table2). 
 
Table 2: In-hospital major adverse cardiac events 
 LVH* 
N=74 
No LVH 
N=386 
p Value 
Mortality 4(5.4%) 14(3.6%) 0.4 
Heart failure/pulmonary 
edema 
2(2.7%) 8(2.07%) 0.6 
Reinfarction 1(1.3%) 1(0.25%) 0.2 
*LVH: Left ventricular hypertrophy 
 
Table3: Univariate analysis for in-hospital major adverse 
cardiac events (MACE) 
 With 
MACE* 
N=30 
Without 
MACE 
N=430 
Pvalue 
Age(years) 68.64±9.91 65.26±13.29 0.2 
Female, n (%)  14(46.6%) 140(32.5%) 0.1 
Hypertension, n (%) 16(53.3%) 265(61.6%) 0.2 
Diabetes mellitus, n (%) 8(26.6%) 158(36.7%) 0.9 
Hyperlipidemia, n (%) 10(33.3%) 96(22.3%) 0.1 
Previous angina, n (%) 18(60%) 372(86.5%) 0.6 
Previous stroke, n (%) 2(6.6%) 14(3.2%) 0.1 
Heart rate (beats/min) 105.4±4.1 99.2±16.7 0.04 
Systolic blood pressure 
(mm Hg) 
119.8±20.7 127.3±21.8 0.1 
Creatinine (mg/dl) 1.84±0.09 1.35±0.9 0.003 
Peak creatine kinase-MB 
(U/L) 
103.4±5.2 87.9±26.1 0.001 
Peak troponin I  (ng/ml) 7.27±1.06 4.39±0.3 0.004 
Electrocardiographic  
left ventricular 
hypertrophy (LVH), n 
(%) 
4(13.3%) 70(16.2%) 0.8 
LV ejection fraction (%) 38.4±9.3 41.2±10.1 0.1 
*Major adverse cardiovascular events 
 
Table 3 demonstrates basic and laboratory findings 
among patients with and without in-hospital MACE. 
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Univariate predictors of in- hospital MACE were:  higher 
levels of CK-MB, cardiac troponin, creatinine and 
tachycardia at admission. In multivariate logistic regression, 
none of the abovementioned factors could predict in-hospital 
MACE independently (table 4). 
 
Table 4: Multivariate regression analysis of independent 
predictors of in-hospital MACE (major adverse cardiac 
events) 
 P 
value 
Odds 
ratio 
95% 
Confidence 
Interval 
Lower Upper 
Heart rate 0.441 0.998 0.993 1.003 
Creatinine 0.484 0.839 0.514 1.371 
Peak creatine kinase-MB 
(U/L) 
0.512 0.999 0.997 1.001 
Peak troponin I   0.149 0.954 0.895 1.017 
 
 
Discussion 
The main findings of the present study are as follows: 1) 
Electrocardiographic LVH was observed in ≈ 16% of a 460 
consecutive first NSTEMI cohort 2) These patients had 
higher levels of cardiac troponin but less likely to undergo 
coronary angiography 3) LVH in ECG was not associated 
with increased in-hospital complications and mortality. 
Though echocardiography is the standard method to 
diagnose LVH, evaluation of left ventricular hypertrophy by 
patients’ ECG is easier than other methods and is easily 
accessible (17, 18). The effect of the ECG LVH on the 
clinical outcomes of patients with acute coronary syndrome, 
had been subject of multiple studies with different results. 
The reported frequency of electrocardiographic LVH in 
present study is more than the previous studies (8, 11, 12, 
13) but approximately in some recent reports (10, 19). 
Different criteria used in these studies might be the main 
cause of different frequency. In the present study, LVH 
patients had significantly higher levels of cardiac enzymes. 
In the setting of NSTEMI, this may be a new finding as most 
of previous studies have shown either no difference in 
troponin or CK-MB level between patients with and without 
electrocardiographic LVH (12,19) or even lower levels have 
been reported (8). In contrast, our study results regarding 
cardiac biomarkers rising resembles one recent study that has 
been conducted in STEMI patients treated with primary 
angioplasty and showed higher enzyme rising and infarct 
size in patients with electrocardiographic LVH [10].One 
possible mechanism may be related to less cardiac reserve 
and more myocardial damage in hypertrophied hearts and 
other mechanism may be due to less capillary density and 
increased oxygen demand. However, the present study did 
not measure infarct size with precise imaging techniques 
such as CMR, so larger studies with accurate myocardial 
imaging are needed to clarify the exact effect of LVH on 
infarct size.  Similar to previous studies (8, 13), patients with 
LVH in the present study were less likely to undergo cardiac 
catheterization but invasive procedure rates were higher than 
previous studies despite similar age group, as 54% of 
patients with LVH in this study underwent coronary 
angiography compared to 43% in the study by Ali et al. and 
31% in GUSTO IV ACS study.  
The exact reason of this more conservative approach in 
the present study is not clear but may related to more 
advanced age and higher prevalence of comorbidity and 
frailty in this cohort. Another possible explanation may be 
related to attribution of ST-segment and T wave changes in 
ECG to LVH induced ST-T changes and not coronary 
ischemia by treating physicians and thus selection of 
conservative approach rather than coronary angiography. 
Definitely in the present study, we did not measure ST-
segment or T wave changes and its prevalence and impact on 
hospital mortality and this needs further studies. In the 
present study, no difference was observed in terms of in-
hospital complications and death between patients with and 
without LVH.  
The main possible explanation for no effect of 
electrocardiographic LVH on in-hospital MACE (major 
adverse clinical event) may be related to coronary 
involvement and revascularization procedure in the current 
study. More than half of patients with LVH had less severe 
forms of coronary artery stenosis (figure 1) and more than 
seventy percent of them underwent percutaneous coronary 
revascularization (figure 2). Hence, better survival is 
anticipated in this group. Another possible cause may be the 
higher prevalence of cardioprotective medication use in 
patients with LVH as 54% and 35% of patients were on beta-
blocker and ASA before admission.   
Similar to the present study, Ali et al. concluded that 
LVH in the ECG had no independent effect on short-term or 
long-term mortality (13). Moreover, Brown stated that the 
presence of electrocardiographic LVH at the time of 
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performing PCI did not independently lead to an increase in 
mortality over a three-year period (14). However, in contrast 
to the present study, some studies indicated that 
electrocardiographic LVH was able to predict the death and 
heart failure (8, 10-12). Westerhout et al. showed that LHV 
was associated with increased 30-day and one-year death 
rate; especially in women (8). Nepper-Christensen et al. 
mentioned that LHV was associated with higher risk of death 
and heart failure-caused admission in patients treated with 
primary angioplasty (10). Georgescu et al. stated that LVH 
criteria in electrography of patients with STEMI who 
underwent thrombolysis was associated with increased 30-
day and one-year mortality (11).   
There is still controversy regarding the role of 
electrocardiographic LVH in predicting clinical outcomes of 
patients with ACS which may be due to the following 
reasons: 1) Difference in sample size; in various studies, 
hospitalized patients varied from 370 to 8000 people; 2) 
difference in the use of LVH electrocardiographic criteria. In 
some studies, Sokolow and in some others, Cornell, or other 
multivariable criteria were used alone or together, which can 
be the cause of the difference in the incidence of LVH in 
patients, and the difference in clinical outcomes of patients. 
There is some evidence that Sokolow criteria have less 
sensitivity for diagnosis of LVH than other criteria if 
echocardiographic data are used as gold standard (20).  The 
main limitations of the present study are:  small number of 
patients with LVH, absence of long-term follow-up, non-
randomized, retrospective and single center nature of study 
as well as lack of detailed echocardiographic data. 
Based on the results of the present study, the use of 
electrocardiographic LVH is not suggested to predict in-
hospital outcomes in patients with first NSTEMI. Moreover, 
considering the different LVH criteria can provide better 
results. Although, echocardiographic evaluation of patients 
and long-term follow up may define better role of 
electrocardiographic LVH in the prediction of patients with 
first NSTEMI.  
In conclusion, the present study showed that among 
patients with first NSTEMI, electrocardiographic LVH was 
not associated with increased in-hospital adverse events. 
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